Skip Navigation


ToxSci Advance Access originally published online on April 12, 2006
Toxicological Sciences 2006 92(1):42-50; doi:10.1093/toxsci/kfj193
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
92/1/42    most recent
kfj193v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schultz, I. R.
Right arrow Articles by Shangraw, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schultz, I. R.
Right arrow Articles by Shangraw, R. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Effect of Short-Term Drinking Water Exposure to Dichloroacetate on its Pharmacokinetics and Oral Bioavailability in Human Volunteers: A Stable Isotope Study

Irvin R. Schultz*,1 and Robert E. Shangraw{dagger}

* Battelle Pacific NW Division, Sequim, Washington 98382; and {dagger} Oregon Health & Science University, Portland, Oregon 97239-3098

Received January 10, 2006; accepted April 6, 2006

Dichloroacetic acid (DCAA) is a by-product of drinking water disinfection, is a known rodent hepatocarcinogen, and is also used therapeutically to treat a variety of metabolic disorders in humans. We measured DCAA bioavailability in 16 human volunteers (eight men, eight women) after simultaneous administration of oral and iv DCAA doses. Volunteers consumed DCAA-free bottled water for 2 weeks to wash out background effects of DCAA. Subsequently, each subject consumed 12C-DCAA (2 mg/kg) dissolved in 500 ml water over a period of 3 min. Five minutes after the start of the 12C-DCAA consumption, 13C-labeled DCAA (0.3 mg/kg) was administered iv over 20 s and plasma 12C/13C-DCAA concentrations measured at predetermined time points over 4 h. Volunteers subsequently consumed for 14 consecutive days DCAA 0.02 µg/kg/day dissolved in 500 ml water to simulate a low-level chronic DCAA intake. Afterward, the 12C/13C-DCAA administrations were repeated. Study end points were calculation of AUC0->{infty}, apparent volume of distribution (Vss), total body clearance (Clb), plasma elimination half-life (t1/2,ß), oral absorption rate (Ka), and oral bioavailability. Oral bioavailability was estimated from dose-adjusted AUC ratios and by using a compartmental pharmacokinetic model after simultaneous fitting of oral and iv DCAA concentration-time profiles. DCAA bioavailability had large interindividual variation, ranging from 27 to 100%. In the absence of prior DCAA intake, there were no significant differences (p > 0.05) in any pharmacokinetic parameters between male and female volunteers, although there was a trend that women absorbed DCAA more rapidly (increased Ka), and cleared DCAA more slowly (decreased Clb), than men. Only women were affected by previous 14-day DCAA exposure, which increased the AUC0->{infty} for both oral and iv DCAA doses (p < 0.04 and p < 0.014, respectively) with a corresponding decrease in the Clb.

Key Words: haloacetic acids; chlorination; GST-zeta.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
M. Jia, B. Coats, M. Chadha, B. Frentzen, J. Perez-Rodriguez, P. A. Chadik, R. A. Yost, G. N. Henderson, and P. W. Stacpoole
Human Kinetics of Orally and Intravenously Administered Low-Dose 1,2-13C-Dichloroacetate.
J. Clin. Pharmacol., December 1, 2006; 46(12): 1449 - 1459.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.